Dong Liang to Antineoplastic Agents
This is a "connection" page, showing publications Dong Liang has written about Antineoplastic Agents.
Connection Strength
0.558
-
John MK, Xie H, Bell EC, Liang D. Development and pharmacokinetic evaluation of a curcumin co-solvent formulation. Anticancer Res. 2013 Oct; 33(10):4285-91.
Score: 0.270
-
Sarkar M, Wang Y, Ekpenyong O, Liang D, Xie H. Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 03; 15(2):e1846.
Score: 0.125
-
You J, Zhao J, Wen X, Wu C, Huang Q, Guan F, Wu R, Liang D, Li C. Chemoradiation therapy using cyclopamine-loaded liquid-lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles. J Control Release. 2015 Mar 28; 202:40-8.
Score: 0.074
-
Liang S, Bian X, Liang D, Sivils JC, Neckers LM, Cox MB, Xie H. Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharm Dev Technol. 2016; 21(1):121-6.
Score: 0.073
-
Meng QH, Xu E, Hildebrandt MA, Liang D, Lu K, Ye Y, Wagar EA, Wu X. Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome. Clin Chem. 2014 Jan; 60(1):222-32.
Score: 0.017